Biomarkers
A four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China
Ecotoxicology and Environmental Safety 2025 July 1 [Link] Lijin Zhu, Shibo Ying, Xin Su, Wenke Yu, Kaili Yan, Wei Shen, Shuaiyue Hu, Zhaoqiang Jiang, Hailing Xia, Lingfang Feng, Yan Zeng, Junqiang Chen, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive malignant tumor of mesothelial origin that develops mainly in the parietal pleura…
Read MoreFrom asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma
Experimental and Molecular Pathology 2025 May 20 [Link] Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, Maria Palmieri, Antonio Giordano, Elisa Frullanti Abstract Background: The incidence of malignant pleural mesothelioma (MPM) has surged due to widespread asbestos exposure, particularly since the mid-20th century. Despite significant advancements in cancer treatment,…
Read MoreBreaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…
Read MoreThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreCytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway
Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the outcomes are poor, necessitating an urgent need to study the mechanism of chemotherapy resistance in mesothelioma cells. Human antigen R (HuR), an RNA-binding protein and…
Read MoreDNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma
Cancer Immunology, Immunotherapy 2025 March 25 [Link] Huilin Zhang, Luanxue Yu, Yunqing Guo, Jiawei Ming, Zhenying Guo Abstract Background: Malignant mesothelioma is a highly aggressive cancer with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME) plays a pivotal role in driving tumor progression, with immune cells influencing disease outcomes. However, the molecular…
Read MoreTelomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review)
International Journal of Oncology 2025 March [Link] Dimitrios Andreikos, Demetrios A Spandidos, Vasiliki Epameinondas Georgakopoulou Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer linked to asbestos exposure and characterized by advanced‑stage disease at presentation. Despite advances in treatment, prognosis remains abysmal, highlighting the imperative for the development of novel biomarkers and treatment approaches.…
Read MoreThe phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes
Journal of Translational Medicine 2025 February 20 [Link] Federica Torricelli, Filomena Spada, Cynthia Bishop, Katrina Todd, Daisuke Nonaka, Nedyalko Petrov, Manuela Terranova Barberio, Alan G Ramsay, Richard Ellis, Alessia Ciarrocchi, Benedetta Apollonio, Andrea Billè Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options. To improve patients management and…
Read MorePotential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MoreThe Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
Medicina 2025 January 16 [Link] Nadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, Delyadil Karakaş Kılıç, Esra Zeynelgil, Yunus Emre Altintaş, Berivan Deniz Çimik, Yeşim Ağyol, Ali Kaan Güren, Pınar Erel, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Abdussamet Çelebi, Nazım Can Demircan, Selver Işık, Rukiye Arıkan, Murat Araz, Serdar Karakaya, Murat Sarı, Osman Köstek, İbrahim…
Read More